Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

By afschroeder • April 27, 2026

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp MS, Houot R, Beitinjaneh A, Zheng D, Chang M, Zhang W, Shen RR, Khalid RD, Kloos I, Wang ML. Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. J Hematol Oncol. 2026 Apr 27. doi: 10.1186/s13045-026-01797-4. Epub ahead of print. PMID: 42036693.

Tags: Brexu-cel, CAR T-cell therapy, Hematology/Oncology, Long-term follow-up, Mantle cell lymphoma, Publications, ZUMA-2

Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach

Idossa D, Hennessy MA, LeVee A, Nanda R, McArthur H, Leon-Ferre RA. Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. Am[...]

Provider Follow-Up and Adherence to Imaging Surveillance Recommendations for Lung Cancer Survivors in a Nationwide Health Care System

Wu JT, Lin N, Adams SV, Asch S, Zeliadt S, Harris AHS, Han SS, Backhus L. Provider Follow-Up and Adherence to Imaging Surveillance Recommendations for[...]

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat[...]